Lyantonde GH
Lyantonde, Uganda
Location status: Recruiting
Location contact
Lilian Tabwenda
CONTACT
NCT Number: NCT06835738
The objective of this research is to understand how antenatal multiple micronutrient supplements (MMS) can be effectively implemented and scaled within the Uganda national health system context to support improved maternal nutrition and birth outcomes. Formative research has been conducted to design the implementation strategies that will be tested in this second phase of the study. The objectives are to:
* Describe the implementation of the MMS intervention (which consists of MMS product, a social behavior change communication (SBCC) strategy, capacity building, MMS supply chain support, monitoring, and evaluation) and explore acceptability, feasibility, fidelity, coverage, and potential for sustainability. * Determine the effect of dispensing MMS in different bottle counts on MMS adherence and ANC attendance among pregnant women. * Determine the cost and budget impact of MMS intervention implementation integrated in the Ugandan ANC service delivery system
Interested in participating?
Request Info0 year–80 year
All sexes
Interventional
Not applicable
Lyantonde, Uganda
Location status: Recruiting
Lilian Tabwenda
CONTACT
Within the context of the existing antenatal care system, investigators will utilize qualitative and quantitative methods to answer the following research questions:
This is a 3-arm quasi-experimental implementation research (IR) study utilizing a mixed methods data collection approach across multiple study populations (e.g., national, regional, and district-level decision makers, healthcare providers, pregnant women, and other community members). The three study arms are: Study Arm #1 (MMS 180-count), Study Arm #2 (MMS 30-count) and Study Arm #3 (MMS 90-count).
The IR will be conducted in 8 districts representing the South Central, Acholi, and Karamoja regions of Uganda. Sufficient MMS will be provided to the 8 districts to ensure full implementation of MMS across all government (public) facilities and private not-for-profit (PNFP) facilities within the 8 study districts. In other words, all pregnant women who attend ANC through either a public or PNFP health facility within the 8 study districts will be offered MMS rather than IFA.
Each district will be assigned to receive a specific "bottle-count" to be provided to all pregnant women attending ANC in that district. All women will be provided with 180 tablets of MMS delivered in the "bottle-count" option assigned to the district where she is seeking services. The 3 "bottle-count" options are: 1) 1 bottle containing 180 tablets dispensed to the pregnant woman attending the first ANC visit; 2) 2 bottles each containing 90 tablets of MMS dispensed at two different time points during pregnancy; or 3) 6 bottles each containing 30 tablets of MMS dispensed monthly over the course of a woman's pregnancy). All pregnant women who are assigned to a 30 or 90 bottle count will continue with that bottle count throughout the women's life of pregnancy and postpartum period.
Each "bottle-count" equates to a study arm. Each of the 3 study regions will have slightly different study arms. The districts/study arms within each region were purposively selected under the formative (phase I) of the study. Because there are 3 districts in both the South-Central Region and the Acholi region, each of the 3 districts will serve as a study arm representing one of the three "bottle-count" options. Because there are only 2 districts in the Karamoja region, there will not be a 90-count study-arm.
The study will undertake data collection at approximately 6 facilities per district, representative of the total number of facilities in the districts. Facilities will be purposively selected after being stratified based on the level of the health facility (health center II, health center III, health center IV, or hospital), ownership (government or PNFP), and geographic location.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for Pregnant women- Enrolled for follow-up throughout pregnancy (sample 1)
Exclusion criteria
for Pregnant women- Enrolled for follow-up throughout pregnancy (sample 1)
Inclusion criteria
for Pregnant women / Women that have recently delivered (single contact) (sample 2)
Exclusion criteria
for Pregnant women / Women that have recently delivered (single contact) (sample 2)
Inclusion criteria
for ANC providers having ANC health education/counseling with pregnant woman(en) observed (sample 3)
Exclusion criteria
for ANC providers having ANC health education/counseling with pregnant woman(en) observed (sample 3) • Healthcare providers that are currently providing ANC health education (group) or ANC individual counseling to a woman(en) that have not provided written informed consent to have the ANC session observed.
Inclusion criteria
for Influential family members (male partners & mothers/mothers-in law) (sample 4)
Exclusion criteria
for Influential family members (male partners & mothers/mothers-in law) (sample 4) • None
Inclusion criteria
for Healthcare Providers- including facility in-charge, ANC providers, Health Assistants, staff in-charge of records, and stores manager (sample 5)
Exclusion criteria
for Healthcare Providers- including facility in-charge, ANC providers, Health Assistants, staff in-charge of records, and stores manager (sample 5)
Inclusion criteria
for Community Health Workers (VHTs) and Mentor Mothers (sample 6) • Voluntary Health Team (VHT), Mentor Mothers, or Para-socials attached to at least one of the study facilities.
Exclusion criteria
for Community Health Workers (VHTs) and Mentor Mothers (sample 6) • None
Inclusion criteria
for National, regional, and district-level stakeholders (sample 7)
Exclusion criteria
for National, regional, and district-level stakeholders (sample 7)
Inclusion criteria
for Pregnant women - interviewed during post-intervention Household Coverage Survey (sample 8)
Exclusion criteria
for Pregnant women - interviewed during post-intervention Household Coverage Survey (sample 8)
MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.
MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.
MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.
Time frame: 3-month post-enrolment, 6-month post-enrolment visit, 6-week postpartum visit
The number of MMS tablets (from a total possible 180 tablets) a pregnant woman consumes (sample 1).
Time frame: 3-month post-enrolment, 6-month post-enrolment visit, 6-week postpartum visit
The frequency of which MMS tablets are consumed by a pregnant woman. (sample group 1)
Time frame: 3-month post-enrolment, 6-month post-enrolment visit, 6-week postpartum visit
The number of ANC visits (from a total possible of 8 visits) a pregnant woman makes throughout her pregnancy (sample 1)
Time frame: 3-month post-enrolment visit, 6-month post-enrolment visit, 6-week postpartum visit
The proportion of pregnant women (sample group 1 and 2) who agree with domain-specific statements which reflect different aspects of MMS acceptability (MMS packaging, MMS physical properties, MMS side effects, and MMS counseling using The Theoretical Framework of Acceptability uses a 5-point Likert scale where 5 is "strongly agree" and 1 is "strongly disagree". Score range 5-35, a higher score reflects higher acceptability.
Time frame: 6 months, 12 months
Healthcare provider acceptability of MMS across multiple domains (e.g., feasibility of delivering counseling and packaging, time burden) (sample group 5). Measured via focus group discussions at two time points during the study (middle and end).
Time frame: 3-months, 6-months, 9-months, and 12-months
Administration of an observation checklist (sample group 3) and a Healthcare Provider Survey (sample 5) at 4 time points during the study
Time frame: 14 months
MMS coverage as assessed by the number of pregnant women or recently pregnant women (sample 8) reporting having been given 180 tablets of MMS as compared to the estimated number of pregnant women in the population (e.g., within the 8 study districts) via post-implementation household survey.
Contact information is provided by the study sponsor or research team.
Johns Hopkins Bloomberg School of Public Health
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05608772
Bariatric Surgery Candidate, Body Weight
Alexandria, Alexandria Governorate, Egypt
View Trial DetailsNCT07271316
Digestive Health, Energy
Fort Worth, Texas, United States
View Trial DetailsNCT07271758
Nutrient Deficiency
Winston-Salem, North Carolina, United States
View Trial DetailsNCT04427852
Behavior, Cognitive Change
College Station, Texas, United States
View Trial Details